Klin Farmakol Farm. 2024;38(2):55-59 | DOI: 10.36290/far.2024.010

Modern pharmacotherapy of Alzheimer's disease

Iva Holmerová1, Martina Nováková2
1 Centrum pro studium dlouhověkosti a dlouhodobé péče UK FHS a Gerontologické centrum, p. o., Praha
2 Centrum následné péče FN Motol, Praha

The article highlights the importance of dementia syndrome and its most common cause, Alzheimer's disease. It presents current options for not only pharmacotherapy but also support for patients and their family members. It delves into the most signifi­cant current development in new treatments for Alzheimer's disease, anti-amyloid therapy, discussing its effects, challenges, and the barriers currently considered in the approval process and practical implementation of these drugs. These medications offer significant hope for patients and their loved ones, demonstrating that it is possible to substantially slow or even halt the progression of Alzheimer's disease (and potentially other neurodegenerative diseases leading to dementia). However, the indications for these drugs are currently quite narrow, and not all patients will benefit from them even in the future. Therefore, it is crucial to fully utilize available symptomatic treatments, both pharmacological and non-pharmacological.

Keywords: dementia, Alzheimer´s disease, angiamyloid therapy, acetylcholinesterase inhibitors, memantin.

Accepted: June 28, 2024; Published: July 15, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holmerová I, Nováková M. Modern pharmacotherapy of Alzheimer's disease. Klin Farmakol Farm. 2024;38(2):55-59. doi: 10.36290/far.2024.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs & aging 15 1999;365-375. Go to original source... Go to PubMed...
    2. Nichols E, Steinmetz JD, Vollsetet SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health. 2022;7(2):e105-e125. Go to original source...
    3. Meijer E, Casanova M, Kim H, et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. Lancet Reg Health Eur. 2022;20:100445. Go to original source... Go to PubMed...
    4. Jönsson L, Tate A. Frisell O, et al. The costs of dementia in Europe: an updated review and meta-analysis. Pharmacoeconomics. 2023;41(1):59-75. Go to original source... Go to PubMed...
    5. Fagundes DF, Costa MT, da Silva Alves BB, et al. Prevalence of dementia in long-term care institutions: a meta-analysis. Jornal Brasileiro de Psiquiatria. 2021;70(1):59-67. Go to original source...
    6. Jirák R, Holmerová I, Borzová C, et al. Demence a jiné poruchy paměti. Grada Publishing a. s., 2009.
    7. Bajtošová R, Holmerová I, Rusina R. Nové pohledy na léčbu demence. Neurol. praxi 2021;22(3):194-200. Go to original source...
    8. Pickett J, Bird C, Ballard C, et al. A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. International journal of geriatric psychiatry. 2018;33(7):900-906. Go to original source... Go to PubMed...
    9. Bradshaw AC, Georges J. Anti-Amyloid Therapies for Alzheimer's Disease: An Alzheimer Europe Position Paper and Call to Action. The Journal of Prevention of Alzheimer's Disease. 2024;11(2):265-273. Go to original source... Go to PubMed...
    10. Wojtunik-Kulesza K, Rudkowska M, Orzeł-Sajdłowska A. Aducanumab - hope or disappointment for Alzheimer's disease. International Journal of Molecular Sciences. 2023;24(5):4367. Go to original source... Go to PubMed...
    11. Heidebrink JL, Paulson HL. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease. Annual Review of Medicine. 2024;75:99-111. Go to original source... Go to PubMed...
    12. Monfared AAT, Ye W, Sardesai A, et al. A path to improved Alzheimer's care: simulating long-term health outcomes of lecanemab in early Alzheimer's disease from the CLARITY AD trial. Neurology and Therapy. 2023;12(3):863-881. Go to original source... Go to PubMed...
    13. Volloch V, Rits-Volloch S. Effect of lecanemab in early Alzheimer's disease: mechanistic interpretation in the amyloid cascade hypothesis 2.0 perspective. Journal of Alzheimer's Disease. 2023;93(4):1277-1284. Go to original source... Go to PubMed...
    14. Cohen S, van Dyck SH, Gee M, et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal of Prevention of Alzheimer's disease. 2023;10(4):771-777. Go to original source... Go to PubMed...
    15. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. Go to original source... Go to PubMed...
    16. Cummings J, Cammann D, Powell J, et al. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. BioDrugs. 2024;38(1):5-22. Go to original source... Go to PubMed...
    17. Atri A, Wessels A, Doty E, et al. Clinical Relevance of Donanemab Treatment (S1. 004). Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024;102:17(supplement 1). Go to original source...
    18. Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414-4424. Go to original source... Go to PubMed...
    19. Holmerová I, Baláčková N, Baumanová M, et al. Strategie České alzheimerovské společnosti P-PA-IA. Geriatire a gerontologe. 2013;2(3):158-164.
    20. Holmerová I. Case management v péči o lidi žijící s demencí: koordinace péče zaměřená na člověka. Fakulta humanitních studií Univerzity Karlovy, 2018.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.